 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2015, vol. 21, issue 3
Subject Area: Medicine - Neurosurgery
Pages: 805-808
DOI: 10.5272/jimab.2015213.805
Published online: 14 July 2015
J of IMAB 2015 Jul-Sep;21(3):805-809
PLASMA EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND BASIC FIBROBLAST GROWTH FACTOR (bFGF) IN PATIENTS WITH BRAIN TUMORS.
Deyan Handzhiev1
, Georgi Kiuchukov2, Yavor Enchev1, Toni Avramov1, Radoslav Georgiev3, Stanislava Varbanova4.
1) Department of Neurosurgery, University Hospital “St. Marina”, Medical University of Varna, Bulgaria
2) Department of Neurosurgery, University Hospital “St. Anna”, Medical University of Varna, Bulgaria
3) Department of Radiology, University Hospital “St. Marina”, Medical University of Varna, Bulgaria
4) Department of Neurology, University Hospital “St. Marina”, Medical University of Varna, Bulgaria.
ABSTRACT:
OBJECTIVE: Angiogenesis and angiogenic growth factors are of basic importance in the development and progresion of brain tumours. The purpose of the study was to evaluate the plasma levels of two angiogenic factors Vascular Endothelial Growth Factor (VEGF) and Basic Fibro blast Growth Factor (bFGF) inpatients with brain tumors and potential possibilities to use them with predictive value.
MATERIAL – METHOD: In order to determine amount of VEGF and FGFb in plasma were examined 35 patients, (glioblastoma multiforme, GBM, n=7; astrocytoma, n=7; meningioma, n=11; and healthy control group, n=10) were analysed. For determination of plasma concentrations of angiogenic factor, highly specific enzyme-linked immuno sorbent assays (ELISAs) were used. The data underwent regression and correlation analysis for estimation of the eventual interrelations.
RESULTS: Median levels of bFGF in glioblastoma patients were higher compared with those with low grade gliomas, meningiomas or healthy patients. Highest levels of VEGF concentrations were detected in plasma derived from patients suffering from LGG. Plasma expression of these angiogenic factors shows dynamic changes pre- and postoperative, but cannot be explained only with tumor resection, grade or type of the tumor, and probably is result of physiological regeneration of the operative wound. No correlation between the survival time of the patients and the plasma levels of the tested growth factors was obtained.
CONCLUSIONS: Expression of VEGF and bFGF in plasma are not reliable marker.
The detectability of the angiogenic factors VEGF and bFGF in the plasma of patients suffering from various types of brain tumours is described. The plasma detectability of the individual angiopoietic factors seems to depend at least partly on the tumour type as well as on tumour progression. This might be of prognostic and therapeutic relevance.
Key words: VEGF, bFGF, GBM, meningioma, astrocytoma, plasma,
- Download FULL TEXT /PDF 565 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Handzhiev D, Kiuchukov G, Enchev Y, Avramov T, Georgiev R, Varbanova S. Plasma expression of Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) in patients with brain tumors. J of IMAB. 2015 Jul-Sep;21(3):805-809. doi: http://dx.doi.org/10.5272/jimab.2015213.805
Correspondence to: Deyan Handzhiev, Medical University of Varna, St Marina Hospital, Department of Neurosurgery; 1, Hristo Smirnenski boul., Varna, Bulgaria; E-mail: deianhandjiev@gmail.com
REFERENCES:
1. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995 Jul;147(1):33-41. [PubMed]
2. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an integrin antagonist. Neurosurgery. 2001 Jan;48(1):151-157. [PubMed]
3. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N Engl J Med. 1995 Dec 28;333(26):1757–1763. [PubMed] [CrossRef]
4. Peles E, Lidar Z., Simon AJ, Grossman R, Nass D. Ram Z. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery. 2004 Sep;55(3):562-567. [PubMed] [CrossRef]
5. Brem S, Tsanaclis AM, Gately S, Gross JL, Herblin WF. Immunolocalizationof basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer. 1992 Dec 1;70(11):2673-2680. [PubMed]
6. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia. 1995 Nov;15(3):339-347. [PubMed]
7. Pötgens AJ, Lubsen NH, van Altena MC, Vermeulen R, Bakker A, Schoenmakers JG, et al. Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem. 1994 Dec 30;269(52):32879-85. [PubMed]
8. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007 Oct;19(10):2003-2012. [PubMed] [CrossRef]
9. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer. 1999 Feb 19;84(1):10-18. [PubMed] [CrossRef]
10. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182-6. [PubMed] [CrossRef]
11. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992 Jun 5;267(16):10931-4. [PubMed]
12. Ilhan A, Gartner W, Neziri D, Czech T, Base W, Hörl WH, et al, Angiogenic factors in plasma of brain tumour patients. Anticancer Res. 2009 Feb;29(2):731-6. [PubMed]
13. Sağlam DA, Ursavaş A, Karadağ M, Yilmaztepe Oral A, Coşkun F, Gözü RO. [The evaluation to relationship between plasma vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer]. [in Turkish] Tuberk Toraks. 2008; 56(1):50-55. [PubMed]
14. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor(VEGF), matrix metalloproteinase- (MMP-3), and BCL-2 inmalignant melanoma. Med Oncol. 2008; 25(4):431-436. [PubMed] [CrossRef]
15. Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, et al. Prognostic significance of plasma hepatocyte growth factor in clear cell renal cell carcinoma: comparison with plasma vascular endothelial growth factor. J Med Invest. 2008 Feb;55(1-2):106-111. [PubMed] [CrossRef
16. Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, et al. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. Cancer Invest. 2008 Apr-May;26(3):250-255. [PubMed] [CrossRef]
17. Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki H, Uchiyama A, et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery. 1996 Mar;119(3):333-339. [PubMed]
18. Iwadate Y, Hayama M, Adachi A, Matsutani T, Nagai Y, Hiwasa T, et al. High serum level of plasminogen activatorinhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res. 2008 Jan-Feb;28(1B):415-418. [PubMed]
19. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007 Dec;130(Pt 12):3336-3341. [PubMed] [CrossRef]
20. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan;11(1):83-95. [PubMed] [CrossRef]
21. Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M, Barnes P, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet. 1994 Jul 9;344(8915):82-86. [PubMed].
Received: 30 November 2014
Published online: 14 July 2015